10.12.2019 I Donation: EDR continues commitment to ALS research
Amyotrophic lateral sclerosis (ALS) is a progressive, currently incurable disease of the motor nervous system in which nerve cells in the brain and spinal cord lose their function and are responsible for controlling the muscles. Patients with ALS have a survival time of only about 3 to 5 years.
Out of 100,000 people in Germany, two to three are diagnosed with ALS every year. One of them is an EDR employee. He got ALS at an unexpectedly early age.
In order to express concern and solidarity, EDR has since been committed to supporting the research for the cause of ALS and establishing effective therapies.
At the end of 2018, a large donation was made to the ALS outpatient clinic of the Charité Berlin, the Charcot Foundation for ALS Research and the association niemALS aufgeben e.V. These facilities will also be financially supported at Christmas 2019.
Both the Charité and the Charcot Foundation concentrate on the realization of research projects on new drugs and therapy methods. The association niemALS aufgeben e.V. is committed to bringing the disease closer to the general public through campaigns and events and supports patients and relatives.
In Germany, about 8,000 people suffer from ALS every year. 2,000 are diagnosed every year; 2,000 die every year. However, there are still too few people affected to receive sufficient research funds to make rapid progress in researching and curing the disease.
"Unfortunately it is not yet known why it hits one or the other, why it starts with some in the arms and others with the language, why some die after a few months and others live on a few years", so Nina Königs, 1st executive committee of the association niemALS aufgeben e.V.
"The missing common denominator complicates the investigation substantially. And yet there are always small advances", Ms. Königs continues. Currently there is only one drug on the market (Riluzol), which prolongs the process by about 3 months. Ms. Königs looks confidently into the future "Last year we were able to provide a larger amount of donations for basic research and we are constantly working with various campaigns to generate additional financial resources".